E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Relapsed resectable and unresectable Osteosarcoma, Ewing Sarcoma. |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Primary Objectives: Group 1 -To determine tumor cell proliferation response after dosing with SCH 717454 in Subjects with resectable osteosarcoma that has relapsed after standard systemic therapy compared to the subject’s historical tumor cell proliferation.
Group 2 -To determine the World Health Organization (WHO) and Response Evaluation Criteria in Solid Tumors (RECIST)-defined radiological response rate to SCH 717454 in subjects with unresectable osteosarcoma refractory to standard therapy.
Group 3 -To determine the WHO and RECIST-defined radiological response rate to SCH 717454 in subjects with Ewing’s sarcoma refractory to standard therapy.
|
|
E.2.2 | Secondary objectives of the trial |
Group 1 To determine time to relapse after dosing with SCH 717454 in subjects with resectable osteosarcoma that has relapsed after standard systemic therapy.
Group 2 and 3: To determine duration of response and time to progression after dosing with SCH717454 in subjects with either unresectable osteosarcoma or refractory Ewing's sarcoma.
All Groups -To evaluate the safety and tolerability of SCH 717454 -To evaluate peripheral blood levels of -Insulin-like Growth Factor I (IGF-I), and IGF-II, -Insulin-like Growth Factor binding protein 2 (IGFBP-2), and Insulin-like Growth Factor binding protein 3 (IGFBP-3), as well as -Insulin-like Growth Factor 1 Receptor (IGF-1R) expression on peripheral blood mononuclear cells (PBMC) by fluorescence activated cell sorting (FACS), -To determine the incidence of anti-SCH 717454 antibodies. -To evaluate serum SCH 717454 concentrations.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. A subject must be 11 years of age or older and may be of any race, and gender;
2. A subject must have a diagnosis of histologically confirmed osteosarcoma or Ewing’s sarcoma;
3. A subject with either: a. relapsed and resectable osteosarcoma (to be included in Group 1) that: - has recurred after prior systemic treatment with active chemotherapy agents (ie, prior exposure to at least one chemotherapy regimen, ie, platinum and doxorubicin); and - must have had the confirmed relapse within 6 months of the immediate prior treatment of the osteosarcoma (longer intervals require discussion with the sponsor); and - must have a surgical or core biopsy tumor specimen (available to determine historical tumor proliferation), and the subject must not have been receiving tumor directed therapy at the time the specimen was obtained, or must have been progressing while on that treatment. The specimen should have been obtained within 8 months of study entry (specimens >8 months before study entry require discussion with the sponsor). b. relapsed and unresectable osteosarcoma (to be included in Group 2) that is refractory to standard therapy, ie has relapsed after prior systemic treatment with active chemotherapy agents (ie, prior exposure to a platinum and doxorubicin containing regimen). The subject must have measurable disease on a CT or MRI study performed during Screening (within 21 days of Day 1); c. Ewing’s sarcoma (to be included in Group 3) that is refractory to standard systemic therapy (ie, prior treatment with at least 3 of these agents: ifosfamide, etoposide, cyclophosphamide, doxorubicin, and vincristine). The subject must have measurable disease on a CT or MRI study performed during Screening (within 21 days of Day 1).
4. A subject >16 years of age must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2; a subject ≤ 16 years of age must have a Karnofsky performance status between 50% and 100% or a Lansky play scale between 50% and 100%;
5. A subject must have a minimum life expectancy of >8 weeks;
6. A subject must have adequate organ function within 3 weeks prior to Day 1 as evidenced by: a. hemoglobin ≥9 g/dL (≥8 g/dL in subjects with Ewing’s sarcoma), b. absolute neutrophil count ≥1.5 x 109/L (≥1.0 x 109/L in subjects with Ewing’s sarcoma), c. platelet count ≥100 x 109/L (≥50 x 109/L in subjects with Ewing’s sarcoma), d. creatinine <1.5 x upper limit of normal (ULN) or creatinine clearance ≥60 mL/min, e. total bilirubin <1.5 x ULN, except for subjects with Gilbert’s disease, f. aspartate aminotransferase (AST)/serum glutamic-oxalacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT) <3 x ULN, or in the presence of documented liver metastases ≤5 x ULN. Subjects with evidence of bone marrow involvement or single hematologic abnormalities (eg, ITP) may be permitted on study on a case-by-case basis. Out-of-range laboratory values at Screening may be repeated once during the Screening Period.
7. A subject (and/or parent/guardian for subjects under the age of legal consent) must give written informed consent and be able to adhere to dose and visit schedules;
8. A female subject and a male subject’s female partner, of childbearing potential, must agree to use a medically accepted method of contraception prior to Screening, while receiving protocol-specified medication, and for 2 months after stopping the medication. Acceptable methods of contraception include abstinence; condoms (male or female) with or without a spermicidal agent; diaphragm or cervical cap with spermicide; medically prescribed intrauterine device; oral, transdermal, or injectable hormonal contraceptive; and surgical sterilization (eg, hysterectomy or tubal ligation). Condoms (male or female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide, and medically prescribed intrauterine devices may be acceptable according local regulations.
|
|
E.4 | Principal exclusion criteria |
The subject will be excluded from entry if ANY of the criteria listed below are met: 1. A subject with a history of another malignancy (with the exception of nonmelanoma skin cancer or carcinoma in situ of the cervix treated with curative intent at least 2 years prior to start of treatment, or other adequately treated malignancy for which the subject has been disease free for ≥5 years);
2. A subject who has known treated or untreated leptomeningeal metastasis, or a metastatic central nervous system lesion;
3. A subject with a history of uncontrolled diabetes mellitus, defined as a hemoglobin A1C of ≥7.5% in a patient with known diabetes mellitus;
4 A subject with a recent myocardial infarction (within the past year); or a subject who at the time of Screening presents with unstable or uncontrolled angina, New York Heart Association (NYHA) Class III or IV congestive heart failure, uncontrolled hypertension, clinically significant cardiac dysrhythmia or clinically significant electrocardiogram (ECG) abnormality;
5. A subject with an active infection;
6. A subject with clinically significant hepatitis at Screening, or a subject that is hepatitis C antibody positive, hepatitis B surface antigen positive, or human immunodeficiency virus (HIV) seropositive;
7. A subject who has been treated with an anti-IGF-1R targeted drug or antibody;
8. A subject with known hypersensitivity to other antibodies, or any accompanying excipients associated with these medications;
9. A subject with persistent, unresolved common terminology criteria for adverse events (CTCAE) ≥ Grade 2 drug-related toxicity associated with previous treatment (inclusion of subjects with persistent neuropathy or hearing loss ≥Grade 2 due to previous treatment require discussion with the sponsor);
10. A subject who has any clinically significant condition or situation, other than the condition being studied that, in the opinion of the investigator, would interfere with the study evaluations or optimal participation in the study;
11. A subject who has received any treatment listed in Table 3 of Section 7.3.2 more recently than the indicated period prior to Screening or must continue to receive treatment that is listed in Table 3 of Section 7.3.2. Any other tumor-directed therapy must be discussed with the sponsor on a case-by-case basis;
12. A female subject who is breast-feeding, pregnant, intends to become pregnant, or has a positive pregnancy test at Screening;
13. A subject participating in any other clinical study with a potentially therapeutic agent or who has received another investigational product within 21 days prior to Day 1;
14. A subject unlikely to complete the study and appropriate follow-up visits.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Group 1 To determine tumor cell proliferation response after dosing with SCH 717454 in subjects with resectable osteosarcoma that has relapsed after standard systemic therapy compared to the subject’s historical tumor cell proliferation.
Group 2 To determine the World Health Organization (WHO) and Response Evaluation Criteria in Solid Tumors (RECIST)-defined radiological response rate to SCH 717454 in subjects with unresectable osteosarcoma refractory to standard therapy.
Group 3 To determine the WHO and RECIST-defined radiological response rate to SCH 717454 in subjects with Ewing’s sarcoma refractory to standard therapy.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Information not present in EudraCT |
E.6.2 | Prophylaxis | Information not present in EudraCT |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Information not present in EudraCT |
E.6.12 | Pharmacoeconomic | Information not present in EudraCT |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 28 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |